Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children

Janet A. Englund, Carol J. Baker, Claire Raskino, Ross E. Mckinney, Marta H. Lifschitz, Barbara Petrie, Mary Glenn Fowler, James D. Connor, Hermann Mendez, Karen O'Donnell, Diane W. Wara, Rachel Behrman, Seth Hetherington, Colin McLaren, Karen Millison, Jack Moye, Molly Nozyce, Deborah A. Pearson, Lynette Purdue, David SchoenfeldGwendolyn B Scott, Stephen A. Spector

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background. A large cohort of antiretroviral therapy-naive, symptomatic, HIV-infected children were enrolled into a controlled therapeutic trial (AIDS Clinical Trials Group Protocol 152), providing an opportunity to describe their clinical and laboratory characteristics and determine age-related distinctions. Methods. Study entry evaluations for 838 of 839 enrolled children were analyzed. Weight, head circumference (if <30 months of age), neuroradiologic imaging of the head, developmental or cognitive status and neurologic examination were assessed. Laboratory studies included hemoglobin, absolute neutrophil count, CD4 cell count, serum amylase, alanine aminotransaminase, p24 antigen and HIV blood culture. Data were categorized by age (3 to <12 months, 12 to <30 months, 30 months to 6 years and ≤6 years). Results. Younger children had significantly higher rates of abnormalities before antiretroviral therapy, especially factors relating to growth and neurologic or cognitive function. Lower CD4+ cell counts and percentages as well as a positive serum p24 antigen correlated with lower weight-for-age Z scores and developmental indices. Conclusions. These data provide a description of the clinical characteristics of HIV-infected US children at the time antiretroviral therapy is initiated for HIV-related symptoms. The high rate of abnormalities of growth, development and cognitive ability that were observed in children <30 months of age demonstrates that treatment strategies should be developed for earlier intervention.

Original languageEnglish
Pages (from-to)1025-1036
Number of pages12
JournalPediatric Infectious Disease Journal
Volume15
Issue number11
DOIs
StatePublished - Nov 1 1996

Fingerprint

HIV
CD4 Lymphocyte Count
HIV Core Protein p24
Head
Therapeutics
Weights and Measures
Aptitude
Neurologic Examination
Amylases
Clinical Protocols
Serum
Growth and Development
Alanine
Cognition
Nervous System
Acquired Immunodeficiency Syndrome
Hemoglobins
Neutrophils
Clinical Trials
Antigens

Keywords

  • Acquired immunodeficiency syndrome
  • antiretroviral therapy
  • children
  • cortical atrophy
  • development
  • didanosine
  • growth failure
  • human immunodeficiency virus
  • infection
  • zidovudine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. / Englund, Janet A.; Baker, Carol J.; Raskino, Claire; Mckinney, Ross E.; Lifschitz, Marta H.; Petrie, Barbara; Fowler, Mary Glenn; Connor, James D.; Mendez, Hermann; O'Donnell, Karen; Wara, Diane W.; Behrman, Rachel; Hetherington, Seth; McLaren, Colin; Millison, Karen; Moye, Jack; Nozyce, Molly; Pearson, Deborah A.; Purdue, Lynette; Schoenfeld, David; Scott, Gwendolyn B; Spector, Stephen A.

In: Pediatric Infectious Disease Journal, Vol. 15, No. 11, 01.11.1996, p. 1025-1036.

Research output: Contribution to journalArticle

Englund, JA, Baker, CJ, Raskino, C, Mckinney, RE, Lifschitz, MH, Petrie, B, Fowler, MG, Connor, JD, Mendez, H, O'Donnell, K, Wara, DW, Behrman, R, Hetherington, S, McLaren, C, Millison, K, Moye, J, Nozyce, M, Pearson, DA, Purdue, L, Schoenfeld, D, Scott, GB & Spector, SA 1996, 'Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children', Pediatric Infectious Disease Journal, vol. 15, no. 11, pp. 1025-1036. https://doi.org/10.1097/00006454-199611000-00018
Englund, Janet A. ; Baker, Carol J. ; Raskino, Claire ; Mckinney, Ross E. ; Lifschitz, Marta H. ; Petrie, Barbara ; Fowler, Mary Glenn ; Connor, James D. ; Mendez, Hermann ; O'Donnell, Karen ; Wara, Diane W. ; Behrman, Rachel ; Hetherington, Seth ; McLaren, Colin ; Millison, Karen ; Moye, Jack ; Nozyce, Molly ; Pearson, Deborah A. ; Purdue, Lynette ; Schoenfeld, David ; Scott, Gwendolyn B ; Spector, Stephen A. / Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. In: Pediatric Infectious Disease Journal. 1996 ; Vol. 15, No. 11. pp. 1025-1036.
@article{bf18a500909545359e645f20f40cbeba,
title = "Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children",
abstract = "Background. A large cohort of antiretroviral therapy-naive, symptomatic, HIV-infected children were enrolled into a controlled therapeutic trial (AIDS Clinical Trials Group Protocol 152), providing an opportunity to describe their clinical and laboratory characteristics and determine age-related distinctions. Methods. Study entry evaluations for 838 of 839 enrolled children were analyzed. Weight, head circumference (if <30 months of age), neuroradiologic imaging of the head, developmental or cognitive status and neurologic examination were assessed. Laboratory studies included hemoglobin, absolute neutrophil count, CD4 cell count, serum amylase, alanine aminotransaminase, p24 antigen and HIV blood culture. Data were categorized by age (3 to <12 months, 12 to <30 months, 30 months to 6 years and ≤6 years). Results. Younger children had significantly higher rates of abnormalities before antiretroviral therapy, especially factors relating to growth and neurologic or cognitive function. Lower CD4+ cell counts and percentages as well as a positive serum p24 antigen correlated with lower weight-for-age Z scores and developmental indices. Conclusions. These data provide a description of the clinical characteristics of HIV-infected US children at the time antiretroviral therapy is initiated for HIV-related symptoms. The high rate of abnormalities of growth, development and cognitive ability that were observed in children <30 months of age demonstrates that treatment strategies should be developed for earlier intervention.",
keywords = "Acquired immunodeficiency syndrome, antiretroviral therapy, children, cortical atrophy, development, didanosine, growth failure, human immunodeficiency virus, infection, zidovudine",
author = "Englund, {Janet A.} and Baker, {Carol J.} and Claire Raskino and Mckinney, {Ross E.} and Lifschitz, {Marta H.} and Barbara Petrie and Fowler, {Mary Glenn} and Connor, {James D.} and Hermann Mendez and Karen O'Donnell and Wara, {Diane W.} and Rachel Behrman and Seth Hetherington and Colin McLaren and Karen Millison and Jack Moye and Molly Nozyce and Pearson, {Deborah A.} and Lynette Purdue and David Schoenfeld and Scott, {Gwendolyn B} and Spector, {Stephen A.}",
year = "1996",
month = "11",
day = "1",
doi = "10.1097/00006454-199611000-00018",
language = "English",
volume = "15",
pages = "1025--1036",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children

AU - Englund, Janet A.

AU - Baker, Carol J.

AU - Raskino, Claire

AU - Mckinney, Ross E.

AU - Lifschitz, Marta H.

AU - Petrie, Barbara

AU - Fowler, Mary Glenn

AU - Connor, James D.

AU - Mendez, Hermann

AU - O'Donnell, Karen

AU - Wara, Diane W.

AU - Behrman, Rachel

AU - Hetherington, Seth

AU - McLaren, Colin

AU - Millison, Karen

AU - Moye, Jack

AU - Nozyce, Molly

AU - Pearson, Deborah A.

AU - Purdue, Lynette

AU - Schoenfeld, David

AU - Scott, Gwendolyn B

AU - Spector, Stephen A.

PY - 1996/11/1

Y1 - 1996/11/1

N2 - Background. A large cohort of antiretroviral therapy-naive, symptomatic, HIV-infected children were enrolled into a controlled therapeutic trial (AIDS Clinical Trials Group Protocol 152), providing an opportunity to describe their clinical and laboratory characteristics and determine age-related distinctions. Methods. Study entry evaluations for 838 of 839 enrolled children were analyzed. Weight, head circumference (if <30 months of age), neuroradiologic imaging of the head, developmental or cognitive status and neurologic examination were assessed. Laboratory studies included hemoglobin, absolute neutrophil count, CD4 cell count, serum amylase, alanine aminotransaminase, p24 antigen and HIV blood culture. Data were categorized by age (3 to <12 months, 12 to <30 months, 30 months to 6 years and ≤6 years). Results. Younger children had significantly higher rates of abnormalities before antiretroviral therapy, especially factors relating to growth and neurologic or cognitive function. Lower CD4+ cell counts and percentages as well as a positive serum p24 antigen correlated with lower weight-for-age Z scores and developmental indices. Conclusions. These data provide a description of the clinical characteristics of HIV-infected US children at the time antiretroviral therapy is initiated for HIV-related symptoms. The high rate of abnormalities of growth, development and cognitive ability that were observed in children <30 months of age demonstrates that treatment strategies should be developed for earlier intervention.

AB - Background. A large cohort of antiretroviral therapy-naive, symptomatic, HIV-infected children were enrolled into a controlled therapeutic trial (AIDS Clinical Trials Group Protocol 152), providing an opportunity to describe their clinical and laboratory characteristics and determine age-related distinctions. Methods. Study entry evaluations for 838 of 839 enrolled children were analyzed. Weight, head circumference (if <30 months of age), neuroradiologic imaging of the head, developmental or cognitive status and neurologic examination were assessed. Laboratory studies included hemoglobin, absolute neutrophil count, CD4 cell count, serum amylase, alanine aminotransaminase, p24 antigen and HIV blood culture. Data were categorized by age (3 to <12 months, 12 to <30 months, 30 months to 6 years and ≤6 years). Results. Younger children had significantly higher rates of abnormalities before antiretroviral therapy, especially factors relating to growth and neurologic or cognitive function. Lower CD4+ cell counts and percentages as well as a positive serum p24 antigen correlated with lower weight-for-age Z scores and developmental indices. Conclusions. These data provide a description of the clinical characteristics of HIV-infected US children at the time antiretroviral therapy is initiated for HIV-related symptoms. The high rate of abnormalities of growth, development and cognitive ability that were observed in children <30 months of age demonstrates that treatment strategies should be developed for earlier intervention.

KW - Acquired immunodeficiency syndrome

KW - antiretroviral therapy

KW - children

KW - cortical atrophy

KW - development

KW - didanosine

KW - growth failure

KW - human immunodeficiency virus

KW - infection

KW - zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0029828510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029828510&partnerID=8YFLogxK

U2 - 10.1097/00006454-199611000-00018

DO - 10.1097/00006454-199611000-00018

M3 - Article

C2 - 8933553

AN - SCOPUS:0029828510

VL - 15

SP - 1025

EP - 1036

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 11

ER -